|
1
|
Karaosmanoğlu AD and Blake MA:
Applications of PET-CT in patients with esophageal cancer. Diagn
Interv Radiol. 18:171–182. 2012.
|
|
2
|
Koshy M, Esiashvilli N, Landry JC, et al:
Multiple management modalities in esophageal cancer: epidemiology,
presentation and progression, work-up, and surgical approaches.
Oncologist. 9:137–146. 2004.
|
|
3
|
Tytgat GN, Bartelink H, Bernards R, et al:
Cancer of the esophagus and gastric cardia: recent advances. Dis
Esophagus. 17:10–26. 2004.
|
|
4
|
Huang J, Zhou Y, Zhang H, et al: A phase
II study of biweekly paclitaxel and cisplatin chemotherapy for
recurrent or metastatic esophageal squamous cell carcinoma: ERCC1
expression predicts response to chemotherapy. Med Oncol.
30:3432013.
|
|
5
|
Emi M, Hihara J, Hamai Y, et al:
Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and
5-fluorouracil for esophageal cancer. Cancer Chemother Pharmacol.
69:1499–1505. 2012.
|
|
6
|
Idelevich E, Kashtan H, Klein Y, et al:
Prospective phase II study of neoadjuvant therapy with cisplatin,
5-fluorouracil, and bevacizumab for locally advanced resectable
esophageal cancer. Onkologie. 35:427–431. 2012.
|
|
7
|
Lorenzen S, Schuster T, Porschen R, et al:
Cetuximab plus cisplatin-5-fluorouracil versus
cisplatin-5-fluorouracil alone in first-line metastatic squamous
cell carcinoma of the esophagus: a randomized phase II study of the
Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol.
20:1667–1673. 2009.
|
|
8
|
Vosmik M, Petera J, Sirak I, et al:
Technological advances in radiotherapy for esophageal cancer. World
J Gastroenterol. 16:5555–5564. 2010.
|
|
9
|
Gao XS: Considerations of treatment
standardization from the procession of NCCN guideline of esophageal
cancer. Chin J Cancer. 29:860–864. 2010.
|
|
10
|
Katsoulis IE, Karoon A, Mylvaganam S and
Livingstone JI: Endoscopic palliation of malignant dysphagia: a
challenging task in inoperable oesophageal cancer. World J Surg
Oncol. 4:382006.
|
|
11
|
Wong SK, Chiu PW, Leung SF, et al:
Concurrent chemoradiotherapy or endoscopic stenting for advanced
squamous cell carcinoma of esophagus: a case-control study. Ann
Surg Oncol. 15:576–582. 2008.
|
|
12
|
Cooper JS, Guo MD, Herskovic A, et al:
Chemoradiotherapy of locally advanced esophageal cancer: long-term
follow-up of a prospective randomized trial (RTOG 85-01). Radiation
Therapy Oncology Group. JAMA. 281:1623–1627. 1999.
|
|
13
|
Minsky BD, Pajak TF, Ginsberg RJ, et al:
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial
of combined-modality therapy for esophageal cancer: high-dose
versus standard-dose radiation therapy. J Clin Oncol. 20:1167–1174.
2002.
|
|
14
|
Lin SH, Wang L, Myles B, et al: Propensity
score-based comparison of long-term outcomes with 3-dimensional
conformal radiotherapy vs intensity-modulated radiotherapy for
esophageal cancer. Int J Radiat Oncol Biol Phys. 84:1078–1085.
2012.
|
|
15
|
Nutting CM, Bedford JL, Cosgrove VP, et
al: A comparison of conformal and intensity-modulated techniques
for oesophageal radiotherapy. Radiother Oncol. 61:157–163.
2001.
|
|
16
|
Mundt AJ, Mell LK and Roeske JC:
Preliminary analysis of chronic gastrointestinal toxicity in
gynecology patients treated with intensity-modulated whole pelvic
radiation therapy. Int J Radiat Oncol Biol Phys. 56:1354–1360.
2003.
|
|
17
|
Uy NW, Woo SY, Teh BS, et al:
Intensity-modulated radiation therapy (IMRT) for meningioma. Int J
Radiat Oncol Biol Phys. 53:1265–1270. 2003.
|
|
18
|
Vicini FA, Sharpe M, Kestin L, et al:
Optimizing breast cancer treatment efficacy with
intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys.
54:1336–1344. 2002.
|
|
19
|
Homs MY, Eijkenboom WM, Coen VL, et al:
High dose rate brachytherapy for the palliation of malignant
dysphagia. Radiother Oncol. 66:327–332. 2003.
|
|
20
|
Homs MY, Steyerberg EW, Eijkenboom WM, et
al: Single-dose brachytherapy versus metal stent placement for the
palliation of dysphagia from oesophageal cancer: multicentre
randomised trial. Lancet. 364:1497–1504. 2004.
|
|
21
|
Russo JK and Rosen L: TomoTherapy
stereotactic body radiation therapy (SBRT) for the salvage
treatment of locally recurrent esophageal adenocarcinoma following
trimodality therapy: a case report. Tumori. 97:406–410. 2011.
|
|
22
|
O’Reilly MS, Boehm T, Shing Y, et al:
Endostatin: an endogenous inhibitor of angiogenesis and tumor
growth. Cell. 88:277–285. 1997.
|
|
23
|
Rong B, Yang S, Li W, et al: Systematic
review and meta-analysis of Endostar (rh-endostatin) combined with
chemotherapy versus chemotherapy alone for treating advanced
non-small cell lung cancer. World J Surg Oncol. 10:1702012.
|
|
24
|
Zhou J, Wang L, Xu X, et al: Antitumor
activity of Endostar combined with radiation against human
nasopharyngeal carcinoma in mouse xenograft models. Oncol Lett.
4:976–980. 2012.
|
|
25
|
Jin F, Ji H, Jia C, et al: Synergistic
antitumor effects of endostar in combination with oxaliplatin via
inhibition of HIF and CXCR4 in the colorectal cell line SW1116.
PLoS One. 7:e471612012.
|
|
26
|
Chang L, Guo F, Lv Y, et al: The
inhibitory effects of Endostar combined with chemotherapy on human
esophageal squamous cell carcinoma xenograft in mice. Mol Biol Rep.
40:669–673. 2013.
|
|
27
|
Zhong Z, Gu X, Zhang Z, et al: Recombinant
human endostatin combined with definitive chemoradiotherapy as
primary treatment for patients with unresectable but without
systemic metastatic squamous cell carcinoma of the oesophagus. Br J
Radiol. 85:e1104–e1109. 2012.
|
